Thermomind News
6 articles
Cancer screening: Dr. Larisa Adamyan & Najeeb Ayoub - ISRAEL21c
ThermoMind, a healthcare company, has won a Horizon grant of 11.5m euro from the European Commission. They are developing a novel, noninvasive, radiation-free and patient-centric modality called ThermoMind, which aims to revolutionize breast cancer screening. The technology also has the potential to detect and diagnose other diseases that impact metabolic functions. The companys objective is to enhance the overall health and wellbeing of individuals by improving the standard of care for breast cancer detection. ThermoMinds approach could increase the chances of successful treatment, improve patient monitoring, and reduce discomfort and anxiety associated with traditional diagnostic methods. The founders, Najeeb and Larisa, are focused on creating employment opportunities and generating novel forms of data in the healthcare industry.
Investment
Safe, painless early breast-cancer detection is on the way - ISRAEL21c
Israeli startup ThermoMind is developing a thermal-sensor-based, contact-free, radiation-free screening modality for detecting early-stage breast tumors. The company is conducting clinical trials with 15 ThermoBreast devices in 11 hospitals across the US, Europe, and Israel. ThermoMinds technology uses infrared sensors developed by SCD for thermal imaging in healthcare. The AI-based thermal image decision support system can detect metabolic and vascular changes caused by cancer within minutes. ThermoMind was founded by Najeeb Ayoub and Larisa Adamyan, who are also a couple. They moved to Israel to start the company and have received a grant of 11.5 million euros from Horizon Europe.
Customers
ThermoMind developing non-invasive early-stage breast cancer detection
ThermoMind, a Haifa-based medical technology start-up, aims to develop a medical device for early-stage breast cancer detection. The company received an 11.6 million Euro grant from Horizon Europe for a clinical study at twelve sites in Israel, Europe, and the United States. ThermoMind was founded in Israel in April 2022 and formed a consortium with eighteen partners, including leading hospitals and research institutes. The company plans to have its product on the market in two years. ThermoMinds thermal scanning device uses high-resolution infrared sensors to capture breast thermograms and analyzes them using advanced artificial intelligence algorithms. The technology is risk-free, non-invasive, and comfortable for patients. ThermoMinds innovation in thermal imaging for breast cancer detection sets new protocols and standards for the modality.
InvestmentPartnersCustomers
סריקה לא פולשנית לזיהוי סרטן השד
Israeli start-up ThermoMind is developing an artificial intelligence (AI) enhanced thermography technology for early detection of breast cancer. The technology identifies abnormal patterns in blood supply and metabolism in the breast area that occur due to the development of cancer cells. The scan is non-invasive and does not require contact with the human body. The company has received a grant of 11.5 million euros from the European Union and has recently applied for a grant from the Chief Scientist for the sake of innovation, hoping to raise an additional million dollars for development next year.
InvestmentExpand
'Fewer women on operating table': New Israeli technology battling breast cancer
Prof. Regina Barzilay from MIT has developed an AI algorithm named Mirai that analyses mammogram x-rays and detects early signs of breast cancer. The system has analyzed nearly 130,000 mammograms and has a success rate twice that of the current system used to assess mammograms. The system is undergoing clinical trials in several countries, including Israel, in partnership with Maccabi Healthcare Services and Assuta Hospital. The AI system is considered a gamechanger in predicting womens risk of developing breast cancer and could help to improve detection and treatment of the disease.
CustomersPartnersExpand
15 מיליון אירו: החוקרים הישראלים שמנסים לנצח את הסרטן
Israeli startup ThermoMind Ltd has received a total grant of 11.5 million euros, including 3.115 million euros from Israels budget, for a four-year project. The company has developed a new scanning technology capable of detecting disturbances in blood vessels caused by tumors. The technology combines new infrared cameras, which can identify minute temperature differences, with artificial intelligence algorithms for efficient analysis of thermal patterns. The grant will enable the company to conduct an international clinical study to promote this breakthrough technology.
Investment
